

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of SSY Group Limited (the “**Company**”) is pleased to announce that Mr. Liu Wenjun (“**Mr. Liu**”) has been appointed as a non-executive Director of the Company with effect from 19 January 2024.

The biographical details of Mr. Liu are set out as below:

Mr. Liu Wenjun, aged 52, currently serves as the general manager of the Xindu Base (新都基地) of Sichuan Kelun Pharmaceutical Company Limited* (“**Sichuan Kelun**”, 四川科倫藥業股份有限公司, a substantial shareholder of the Company interested in approximately 20.43% of the issued share capital of the Company), a position he has taken since 2013. He was the general manager of Kunming Nanjiang Pharmaceutical Co., Ltd.* (昆明南疆製藥有限公司) from 2005 to 2013. He served as a workshop supervisor of Sichuan Kelun from 2002 to 2005, and a technician at the Sichuan Antibiotics Laboratory of the National Medical Products Administration* (國家醫藥管理局四川抗菌素研究所) from 1996 to 2002.

Mr. Liu graduated from Chengdu University of Traditional Chinese Medicine with a Bachelor of Science degree and holds the qualification of a Senior Engineer* (正高級工程師) in the People’s Republic of China.

Mr. Liu has entered into a service contract with the Company for a term of three years and his appointment is subject to retirement by rotation and re-election at the next following annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Liu is entitled to receive a director’s fee of HK\$228,000 per annum which is determined on the recommendation of the remuneration committee of the Board with reference to his qualifications, experience, duties and responsibilities in the Company, the remuneration policy of the Company and prevailing market rate.

Save as disclosed above, as at the date of this announcement, Mr. Liu (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) does not have any other major appointments and professional qualifications.

As at the date of this announcement, save as disclosed above, Mr. Liu does not have (i) any interests in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) any relationship with any Director, senior management or substantial or controlling shareholders of the Company.

Save as disclosed above, the Directors are not aware of any other matter in relation to the appointment of Mr. Liu that need to be brought to the attention of the shareholders of the Company, and there is no information relating to the appointment of Mr. Liu that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Company would like to take this opportunity to express its warmest welcome to Mr. Liu for joining the Board.

By Order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 19 January 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.

* *For identification purpose only*